Skip to main content

Table 5 Impact from dimensions of the CAREGIVERS questionnaire and sociodemographic, clinical and healthcare system variables

From: Psychosocial and economic impact of rheumatic diseases on caregivers of Mexican children

  Global Emotional Social Financial Work Family Patient# Couple° Spirituality Networks&
Total
n = 200
36 (31–41) 11 (10–13) 6 (4–7) 3 (2–4) 6 (1–7) 8 (7–10) 0 (0–1) 0 (0–1) 1 (0–1) 0 (0–4)
Caregiver’s gender (Male)* 37 (33–40) 11 (10–13) 5 (4–7) 3 (2–4) 7 (6–8)a 8 (6–9) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–4)
Patient’s gender
(Male)*
37 (33–42) 12 (11–13)a 6 (4–7) 3 (2–4) 6 (0–7) 9 (7–10) 0 (0–1) 1 (0–1) 1 (0–1) 0 (0–4)
Housewife* 36 (29–40)c 11 (10–13) 5.5 (4–7) 3 (1–4) 1 (0–6)b 9 (8–11)c 0 (0–1) 0 (0–1) 1 (0–1) 0 (0–4)
Paid employment* 36 (32–42)c 11
(10–13)
6 (4–7) 3 (1–4) 6 (6–7)b 8 (6–9)c 0 (0–1) 0 (0–1) 1 (0–1) 0 (0–4)
Partner (No)* 39 (33–44)b 11
(10–13)
6.5 (5–7)a 4 (3–5)a 6 (6–7) 8.5 (6–11) 0 (0–1) 0 (0–0)a 1 (0–1) 0.5 (0–4)a
Education ≤9 years* 36 (31–40) 11 (10–13) 6 (4–7) 4 (2–4)b 6 (0–7)a 8 (8–10) 0 (0–0) 0 (0–1) 1 (0–1) 0 (0–3)c
Education > 9 years* 36 (32–42) 11 (10–13) 5 (4–7) 3 (1–4)b 7 (6–7)a 8 (6–10) 0 (0–1) 0 (0–1) 1 (0–1) 0 (0–4)c
JIA** 36 (31–41) 11 (10–13) 5 (4–7)a 3 (1–4)a 6 (1–7) 9 (7–10) 0 (0–1)a 1 (0–1) 1 (0–1)c 0 (0–4)
JDM** 33.5 (30–39) 11 (9–12) 5.5 (4–6)a 4 (2–4)a 6 (0–7) 6 (6–9) 0 (0–1)a 0 (0–1) 0.5 (0–1)c 0 (0–1)
JSLE** 36 (33–42) 11 (10–13) 6 (5–8)a 3 (3–4)a 6 (1–7) 8 (6–10) 0 (0–0)a 0 (0–1) 0 (0–1)c 0 (0–4)
Cutaneous features* 37.5 (32–42) 11 (10–13) 6 (5–7)a 4 (3–4)a 6 (0–7) 8.5 (7–10) 0 (0–0)c 0 (0–1) 0.5 (0–1) 0 (0–4)
Musculoskeletal features*d 36 (31–41) 11 (10–13) 5 (4–7) 3 (2–4) 6 (0–7) 9 (7–10) 0 (0–1)a 0 (0–1) 1 (0–1) 0 (0–4)
Systemic features*e 37 (32–42) 11.5 (10–13) 6 (5–7)a 4 (2–4)a 6 (1–7) 8.5 (7–11) 0 (0–0)a 0 (0–1) 1 (0–1) 0 (0–4)
Hospitalization (Yes)* 36 (31–40) 11 (10–13) 6 (4–7)c 3.5 (2–4)a 6 (0–7) 8 (6–10) 0 (0–0)a 0 (0–1) 1 (0–1) 0 (0–4)
Disability (Yes)* 36 (31–40) 11 (10–13) 6 (5–8)a 4 (3–5)a 6 (0–6)a 9 (8–10) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–4)
Active Disease (Yes)* 36 (32–41) 11 (10–13) 6 (5–7)a 4 (3–4)a 6 (0–6)a 9 (7–10) 0 (0–1) 0 (0–1) 1 (0–1) 0 (0–4)
Treatment (Yes)* NSAID 37 (31–42)c 11 (10–13)c 6 (4–7) 3 (2–4)a 6 (0–7)a 9 (8–10)c 0 (0–1) 1 (0–1)a 1 (0–1) 0 (0–4)
DMARD 36 (32–40) 11 (10–13) 5 (4–7) 3 (1–4)c 6 (1–7) 8 (7–10) 0 (0–1) 0 (0–1) 1 (0–1) 0 (0–4)
GC 36.5 (32–41) 11 (10–13) 6 (5–7)a 4 (3–4)b 6 (0–7) 8 (7–10) 0 (0–0)a 0 (0–1) 0.5 (0–1) 0 (0–4)
bDMARD (No) 36 (32–41)a 11 (10–13) 6 (4–7)a 3 (2–4)a 6 (0–7) 9 (7–11)c 0 (0–1) 0 (0–1) 1 (0–1) 0 (0–4)
PartC** 37 (32–41)a 11 (10–13) 6 (5–7)b 4 (3–4)b 6 (0–6)b 9 (8–10)a 0 (0–1)a 0 (0–1) 1 (0–1) 0 (0–4)
FullC** 33 (31–36)a 11 (10–12) 4 (3–6)b 1 (1–2)b 7 (6–7)b 8 (6–9)a 0 (0–1)a 0 (0–1) 1 (0–1) 0 (0–2)
PRI** 34.5 (28–45)a 12.5 (9–13) 4.5 (3–6)b 1.5 (1–3)b 7 (1–8)b 7.5 (6–10)a 1 (0–1)a 0.5 (0–1) 1 (0–1) 2 (0–4)
More than one hour to the center * 36 (32–40) 11 (10–13) 6 (4–7)a 3.5 (2–4)a 6 (0–7)c 9 (8–10)a 0 (0–1) 0 (0–1) 1 (0–1) 0 (0–2)a
  1. Note: All values are expressed as median (IQR). IQR Interquartile range, JIA Juvenile Idiopathic Arthritis, JSLE Juvenile Systemic Lupus Erythematosus, JDM Juvenile Dermatomyositis, NSAID Nonsteroidal anti-inflammatory drugs, DMARD Disease-modifying antirheumatic drugs, GC Systemic Glucocorticoids, bDMARD Biological therapy
  2. PartC Partial Coverage Healthcare system, FullC Total Coverage Healthcare system, PRI Private Healthcare System
  3. a p < 0.05
  4. b p < 0.001
  5. c Tendency
  6. d Includes arthritis and myositis
  7. e Includes neurological, hematological, pulmonary, gastrointestinal, cardiovascular, nephritis, serositis, adenomegaly, hepatomegaly, hepatitis, thyroiditis and uveitis manifestations
  8. * Analyzed with Chi square test
  9. ** Analyzed with Kruskal-Wallis test
  10. # Relationship of the caregiver with the patient
  11. ° Relationship of the caregiver with partner
  12. & Social Network
\